Literature DB >> 24618544

Acute effects of sildenafil and dobutamine in the hypertrophic and failing right heart in vivo.

Asger Andersen1, Jan M Nielsen, Sivagowry Rasalingam, Erik Sloth, Jens Erik Nielsen-Kudsk.   

Abstract

Abstract The purpose of this study was to investigate whether acute intravenous administration of the phosphodiesterase type 5 (PDE-5) inhibitor sildenafil in a single clinically relevant dose improves the in vivo function of the hypertrophic and failing right ventricle (RV). Wistar rats ([Formula: see text]) were subjected to pulmonary trunk banding (PTB) causing RV hypertrophy and failure. Four weeks after surgery, they were randomized to receive an intravenous bolus dose of sildenafil (1 mg/kg; [Formula: see text]), vehicle ([Formula: see text]), or dobutamine (10 μg/kg; [Formula: see text]). Invasive RV pressures were recorded continuously, and transthoracic echocardiography was performed 1, 5, 15, 25, 35, 50, 70, and 90 minutes after injecting the bolus. Cardiac function was compared to baseline measurements to evaluate the in vivo effects of each specific treatment. The PTB procedure caused significant hypertrophy, cardiac fibrosis, and reduction in RV function evaluated by echocardiography (TAPSE) and invasive pressure measurements. Sildenafil did not improve the function of the hypertrophic failing right heart in vivo, measured by TAPSE, RV systolic pressure (RVsP), and dp/dtmax. Dobutamine improved RV function 1 minute after injection measured by TAPSE ([Formula: see text] vs. [Formula: see text] cm; [Formula: see text]), RVsP ([Formula: see text] vs. [Formula: see text] mmHg; [Formula: see text]), and dp/dtmax ([Formula: see text] vs. [Formula: see text] mmHg/s; [Formula: see text]). Acute administration of the PDE-5 inhibitor sildenafil in a single clinically relevant dose did not modulate the in vivo function of the hypertrophic failing right heart of the rat measured by echocardiography and invasive hemodynamics. In the same model, dobutamine acutely improved RV function.

Entities:  

Year:  2013        PMID: 24618544      PMCID: PMC4070794          DOI: 10.1086/674327

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  32 in total

1.  Hemodynamic effects of sildenafil in men with severe coronary artery disease.

Authors:  H C Herrmann; G Chang; B D Klugherz; P D Mahoney
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

2.  Right and left ventricular function after chronic pulmonary artery banding in rats assessed with biventricular pressure-volume loops.

Authors:  Matthijs J Faber; Michiel Dalinghaus; Inge M Lankhuizen; Paul Steendijk; Wim C Hop; Regien G Schoemaker; Dirk J Duncker; Jos M J Lamers; Willem A Helbing
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-05-05       Impact factor: 4.733

3.  Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure.

Authors:  Harm J Bogaard; Ramesh Natarajan; Scott C Henderson; Carlin S Long; Donatas Kraskauskas; Lisa Smithson; Ramzi Ockaili; Joe M McCord; Norbert F Voelkel
Journal:  Circulation       Date:  2009-11-02       Impact factor: 29.690

4.  Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis.

Authors:  Brian R Lindman; Alan Zajarias; José A Madrazo; Jay Shah; Brian F Gage; Eric Novak; Stephanie N Johnson; Murali M Chakinala; Tara A Hohn; Mohammed Saghir; Douglas L Mann
Journal:  Circulation       Date:  2012-03-25       Impact factor: 29.690

5.  Effects of sildenafil on hypoxic pulmonary vascular function in dogs.

Authors:  Pierre Fesler; Alberto Pagnamenta; Benoit Rondelet; François Kerbaul; Robert Naeije
Journal:  J Appl Physiol (1985)       Date:  2006-06-15

6.  Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide.

Authors:  John J Lepore; Anjli Maroo; Luca M Bigatello; G William Dec; Warren M Zapol; Kenneth D Bloch; Marc J Semigran
Journal:  Chest       Date:  2005-05       Impact factor: 9.410

7.  Differential expression of PDE5 in failing and nonfailing human myocardium.

Authors:  Xiaoyin Shan; Michael P Quaile; Jeffery K Monk; Benjamin French; Thomas P Cappola; Kenneth B Margulies
Journal:  Circ Heart Fail       Date:  2011-12-01       Impact factor: 8.790

8.  Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension.

Authors:  Ioana R Preston; James R Klinger; Jeanne Houtches; David Nelson; Harrison W Farber; Nicholas S Hill
Journal:  Respir Med       Date:  2005-12       Impact factor: 3.415

9.  Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs.

Authors:  A Sugiyama; Y Satoh; H Shiina; A Takahara; M Yoneyama; K Hashimoto
Journal:  J Cardiovasc Pharmacol       Date:  2001-12       Impact factor: 3.105

10.  Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH).

Authors:  J Suntharalingam; R J Hughes; K Goldsmith; N Doughty; P George; M Toshner; K K Sheares; J Pepke-Zaba
Journal:  Vascul Pharmacol       Date:  2007-02-12       Impact factor: 5.773

View more
  2 in total

1.  Comparison of preventive effect of sildenafil and therapeutic effect of sildenafil treatment in rats with monocrotaline-induced pulmonary arterial hypertension.

Authors:  Rieko Yoshiyuki; Ryuji Fukushima; Ryo Tanaka; Noboru Machida
Journal:  J Vet Med Sci       Date:  2016-06-17       Impact factor: 1.267

2.  Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart.

Authors:  Sarah Holmboe; Asger Andersen; Rebekka V Jensen; Hans Henrik Kimose; Lars B Ilkjær; Lei Shen; Lucie H Clapp; Jens Erik Nielsen-Kudsk
Journal:  Pulm Circ       Date:  2017-05-30       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.